Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-18-016080
Filing Date
2018-11-16
Accepted
2018-11-16 17:00:41
Documents
10
Period of Report
2018-12-18
Effectiveness Date
2018-11-16

Document Format Files

Seq Description Document Type Size
1 PRELIMINARY PROXY STATEMENT def14a1118_actiniumpharma.htm DEF 14A 505224
2 GRAPHIC image_001.jpg GRAPHIC 25910
3 GRAPHIC image_002.jpg GRAPHIC 4265
4 GRAPHIC image_003.jpg GRAPHIC 44582
5 GRAPHIC image_004.jpg GRAPHIC 16282
6 GRAPHIC image_005.jpg GRAPHIC 19200
7 GRAPHIC image_006.jpg GRAPHIC 10519
8 GRAPHIC image_007.jpg GRAPHIC 21995
9 GRAPHIC proxy1.jpg GRAPHIC 204815
10 GRAPHIC proxy2.jpg GRAPHIC 255554
  Complete submission text file 0001213900-18-016080.txt   1338057
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 181190474
SIC: 2834 Pharmaceutical Preparations